News
GILD slides 2.6% after FDA halts trials for HIV candidates, GS-1720 and GS-4182, over safety concerns in patients.
The U.S. Food and Drug Administration has paused Gilead Sciences' trials testing a combination of two of its experimental HIV ...
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...
The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of ...
17h
GlobalData on MSNGilead hit with FDA clinical hold for batch of HIV trialsDecreasing CD4 and lymphocyte counts in some participants receiving an oral combination therapy led to holds in the study.
Gilead underscored its faith in the combo therapy and pledged to work with regulators to resolve the hold, which has paused ...
Gilead has been hit with a clinical hold from the FDA for five tests of its experimental HIV combination treatment amid ...
On some negative news about one of its investigational programs, the stock of pharmaceutical company Gilead Sciences (NASDAQ: ...
RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb , licensed an experimental drug and diagnostic agent for ...
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.
Gilead’s HIV treatment trials involving an investigational integrase strand inhibitor (GS-1720) and an investigational capsid inhibitor (GS-4182) have been put on clinical hold by the Food and Drug ...
12don MSN
Walmart's Flipkart has secured a lending licence from the Indian central bank and banking regulator, enabling it to offer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results